Lonza secures exclusive license to use Qurient CDK7 inhibitors for dual-payload ADCs

By Public Technologies
  • Lonza signed an exclusive license deal with Qurient for use of Qurient’s CDK7 inhibitors in dual-payload antibody-drug conjugates.
  • Collaboration launches SYN-duo® CC, combining exatecan with a CDK7 inhibitor as an off-the-shelf linker-payload for ADC developers.
  • Lonza can create additional dual-payload combinations pairing the CDK7 inhibitor with other payloads on its proprietary ADC platform.
  • Move expands Lonza’s proprietary technology offering, aiming to strengthen its position in the growing ADC market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lonza Group Ltd. published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2413778_en) on October 12, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk